You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

~ Buy the MULTRYS (cupric sulfate; manganese sulfate; selenious acid; zinc sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

MULTRYS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Multrys patents expire, and when can generic versions of Multrys launch?

Multrys is a drug marketed by Am Regent and is included in one NDA. There is one patent protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in MULTRYS is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this compound. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Multrys

Multrys was eligible for patent challenges on April 30, 2023.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

US Patents and Regulatory Information for MULTRYS

MULTRYS is protected by one US patents and one FDA Regulatory Exclusivity.

Patents protecting MULTRYS


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting MULTRYS

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Am Regent MULTRYS cupric sulfate; manganese sulfate; selenious acid; zinc sulfate SOLUTION;INTRAVENOUS 209376-003 Jun 30, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Am Regent MULTRYS cupric sulfate; manganese sulfate; selenious acid; zinc sulfate SOLUTION;INTRAVENOUS 209376-003 Jun 30, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MULTRYS

See the table below for patents covering MULTRYS around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2022006426 ⤷  Try a Trial
European Patent Office 4175615 COMPOSITIONS D'OLIGO-ÉLÉMENTS, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE) ⤷  Try a Trial
South Korea 20230058047 미량 원소 조성물, 그 제조 및 사용 방법 ⤷  Try a Trial
Canada 3186578 COMPOSITIONS D'OLIGO-ELEMENTS, LEURS PROCEDES DE FABRICATION ET D'UTILISATION (TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE) ⤷  Try a Trial
China 116096423 微量元素组合物、制备方法及应用 (Microelement composition, preparation method and application) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.